Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

28

Revenue 2017

Ibrance

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Ibrance was produced by Pfizer.

Pfizer’s Ibrance misses the mark in early breast cancer

Pfizer’s Ibrance misses the mark in early breast cancer

While the PALLAS study missed the mark, Pfizer is still holding out hope for another study of Ibrance, PENELOPE-B, which is due to produce results later this year. ... The PENELOPE-B study is evaluating Ibrance in patients with early breast cancer at

20 for 2020 – Five pharma leaders to watch in 2020

20 for 2020 – Five pharma leaders to watch in 2020 to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance (palbociclib) and arthritis drug Xeljanz (tofacitinib), among others.

Vyndaqel a bright spot as Pfizer comes under pressure

Vyndaqel a bright spot as Pfizer comes under pressure The company’s fourth-quarter results saw a 9% drop in revenues to $12.69bn, with breast cancer drug Ibrance (palbociclib) and Xeljanz (tofacitinib) for rheumatoid arthritis both growing but missing ... Ibrance was up 15% to $1.28bn in the quarter,

Integrating electronic health records into clinical trials

Integrating electronic health records into clinical trials Pfizer, for example, won an expanded FDA label for breast cancer drug Ibrance on the strength of data from sources including EHRs.

NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata

NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata Ibrance. Pfizer received a positive answer from the cost-effectiveness watchdog, with NICE approving its breast cancer drug Ibrance (palbociclib) for use on the Cancer Drugs Fund. ... Like Ibrance, AZ’s drug will be recommended for use within the CDF

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics